Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2009 - 2026)

Vertex Pharmaceuticals' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 1031400000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 59.59% year-over-year to 1031400000.0; the TTM figure through Mar 2026 stood at 4338300000.0 (up 538.7% YoY), while the FY2025 annual figure was 3953200000.0, up 838.09% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 1031400000.0, down from 1191100000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 1191100000.0 in Q4 2025, with the low at 3593600000.0 in Q2 2024.
• The 5-year median for Income from Continuing Operations is 930500000.0 (2022), against an average of 670035294.12.
• The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations soared 1109.7% in 2022, then slumped 492.44% in 2024.
• Vertex Pharmaceuticals' Income from Continuing Operations stood at 818900000.0 in 2022, then climbed by 18.31% to 968800000.0 in 2023, then retreated by 5.76% to 913000000.0 in 2024, then soared by 30.46% to 1191100000.0 in 2025, then retreated by 13.41% to 1031400000.0 in 2026.
• Business Quant data shows VRTX's Income from Continuing Operations at 1031400000.0 in Q1 2026, 1191100000.0 in Q4 2025, and 1082900000.0 in Q3 2025.